Pancreatic Cancer Research

ResearcherNorth Dakota State UniversityActive in the last 2 years

Katie M. Reindl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7880-3845; OpenAlex author ID A5058111868; NIH RePORTER profile ID 10135415. Sources: OpenAlex.

Their work

Papers
19 (first author 4, last author 8)
Trials
0
Grants
2
Labs led
1
Collaborators
41
Papers, trials and grants by year

2014: 4 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper, 1 grant · 2021: 1 paper · 2022: none · 2023: none · 2024: 4 papers · 2025: 3 papers · 2026: 1 paper, 1 grant

Papers 19

  1. Mevalonate pathway in pancreatic ductal adenocarcinoma: Mechanisms driving metabolic and cellular plasticity. First author DOI 10.1016/j.cpt.2025.06.004↗
  2. AGR2 knockdown induces ER stress and mitochondria fission to facilitate pancreatic cancer cell death. Last author DOI 10.1016/j.bbamcr.2024.119854↗
  3. GSTP1 knockdown induces metabolic changes affecting energy production and lipid balance in pancreatic cancer cells. First author DOI 10.1080/23723556.2025.2518773↗
  4. Multiomics analysis of GSTP1 knockdown pancreatic cancer cells reveals key regulators of redox and metabolic homeostasis. Last author DOI 10.1242/bio.061986↗
  5. Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer. Co-author DOI 10.1016/j.biopha.2024.116743↗
  6. Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse model of pancreatic cancer. Co-author DOI 10.1016/j.ijpharm.2024.124753↗
  7. Advancements in Preclinical Models of Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000002277↗
  8. Extracellular Signal-Regulated Kinase Inhibitor SCH772984 Augments the Anti-Cancer Effects of Gemcitabine in Nanoparticle Form in Pancreatic Cancer Models. Last author DOI 10.22088/ijmcm.bums.13.3.220↗
  9. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.0c00499↗
  10. Glutathione S-Transferase pi-1 Knockdown Reduces Pancreatic Ductal Adenocarcinoma Growth by Activating Oxidative Stress Response Pathways. Last author DOI 10.3390/cancers12061501↗
  11. JNK inhibition blocks piperlongumine-induced cell death and transcriptional activation of heme oxygenase-1 in pancreatic cancer cells. Last author DOI 10.1007/s10495-019-01553-9↗
  12. Microenvironment-sensing, nanocarrier-mediated delivery of combination chemotherapy for pancreatic cancer. Co-author DOI 10.1007/s12079-019-00514-w↗
  13. Epigenomics of Pancreatic Cancer: A Critical Role for Epigenome-Wide Studies. First author DOI 10.3390/epigenomes3010005↗
  14. Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models. Last author DOI 10.18632/oncotarget.23623↗
  15. Transcriptome Analysis of Piperlongumine-Treated Human Pancreatic Cancer Cells Reveals Involvement of Oxidative Stress and Endoplasmic Reticulum Stress Pathway… Last author DOI 10.1089/jmf.2015.0152↗
  16. Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage. Last author DOI 10.1016/j.toxrep.2014.05.011↗
  17. Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. Co-author DOI 10.1021/mp500108p↗
  18. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signa… Co-author DOI 10.1186/1471-2407-14-686↗
  19. Hyperglycemia regulates TXNIP/TRX/ROS axis via p38 MAPK and ERK pathways in pancreatic cancer. Co-author DOI 10.2174/1568009614666140331231658↗

Grants 2

  1. Biostatistics and Bioinformatics Core Facility P20GM109024↗
  2. GSTP1 as a therapeutic target for pancreatic cancer R15CA249714↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jenna N. Duttenhefner · 3 shared papers, 2025–2026 · strength 1.53
  2. Philip Salu · 4 shared papers, 2024–2025 · strength 1.38
  3. Buddhadev Layek · 2 shared papers, 1 shared grant, 2024–2026 · strength 0.96
  4. Mohiuddin Quadir · 3 shared papers, 1 shared grant, 2019–2026 · strength 0.95
  5. Sanku Mallik · 4 shared papers, 1 shared grant, 2014–2026 · strength 0.95
  6. Megan Orr · 3 shared papers, 1 shared grant, 2018–2026 · strength 0.82
  7. Rahul Raj Singh · 4 shared papers, 2019–2025 · strength 0.80
  8. Rick J. Jansen · 1 shared paper, 1 shared grant, 2019–2026 · strength 0.62
  9. John Curlee Wilkinson · 1 shared paper, 1 shared grant, 2018–2026 · strength 0.54
  10. Erxi Wu · 2 shared papers, 1 shared grant, 2014–2026 · strength 0.54
  11. Bin Guo · 1 shared paper, 1 shared grant, 2014–2026 · strength 0.50
  12. Paras Mani Giri · 2 shared papers, 2024 · strength 0.50
  13. Gauthami Nair · 3 shared papers, 2019–2024 · strength 0.49
  14. Priyanka Ray · 3 shared papers, 2019–2024 · strength 0.49
  15. Sathish Venkatachalem · 1 shared grant, 2026 · strength 0.46
  16. Jiha Kim · 1 shared grant, 2026 · strength 0.46
  17. Ang Guo · 1 shared grant, 2026 · strength 0.46
  18. Mark T Hamann · 1 shared grant, 2026 · strength 0.46
  19. Roberto Gomes · 1 shared grant, 2026 · strength 0.46
  20. Jagdish Singh · 1 shared grant, 2026 · strength 0.46
  21. Estelle Leclerc · 1 shared grant, 2026 · strength 0.46
  22. Elisabetta Liverani · 1 shared grant, 2026 · strength 0.46
  23. Yongki Choi · 1 shared grant, 2026 · strength 0.46
  24. Guodong Liu · 1 shared grant, 2026 · strength 0.46
  25. Jiyan Mohammad · 3 shared papers, 2018–2020 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.